Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

Ozempic and other weight loss drugs have found their home in Kentucky, even though researchers from Washington University in ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

Whether it is prescribed for diabetes or weight loss, Ozempic and other weight- loss drugs have found their home in Kentucky, ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...